Table 1.
Baseline Characteristics of Included Patients Based On the Presence of Liver Fibrosis (Defined as FibroScan TE Value ≥7.9 kPa)
| Characteristics | No Fibrosis (n = 371) | Fibrosis (n = 134) | P value |
|---|---|---|---|
| Age (years), mean (IQR) | 65 (56‐74) | 69 (61‐77) | 0.001 |
| Male sex, n (%) | 280 (75) | 115 (86) | 0.01 |
| BMI (kg/m2), mean (IQR) | 27 (24‐30) | 28 (24‐31) | 0.5 |
| Nicotine consumption (pack years), mean (IQR) | 22 (0‐36) | 25 (0‐40) | 0.6 |
| Alcohol consumption (g/day), mean (IQR) | 5.70 (1‐10) | 6.15 (0‐11) | 0.5 |
| Intake of statins, n (%) | 259 (70) | 95 (71) | 0.8 |
| Intake of antidiabetic medication, n (%) | 65 (18) | 39 (29) | 0.005 |
| Triglycerides (mg/dL) mean (IQR) | 141 (84‐170) | 126 (71‐158) | 0.04 |
| Cholesterin, mean (IQR) | 180 (148‐208) | 154 (120‐187) | <0.001 |
| LDL (mg/dL), mean (IQR) | 100 (75‐122) | 85 (57‐104) | <0.001 |
| HDL (mg/dL), mean (IQR) | 51 (38‐60) | 46 (34‐54) | 0.01 |
| Bilirubin (mg/dL), mean (IQR) | 0.6 (0.4‐0.7) | 0.7 (0.4‐1.0) | <0.001 |
| γGT (U/L), mean (IQR) | 42 (19‐48) | 125 (43‐137) | <0.001 |
| AST (U/L), mean (IQR) | 30 (20‐31) | 38 (22‐43) | <0.001 |
| ALT (U/L), mean (IQR) | 26 (16‐31) | 39 (17‐40) | 0.004 |
| INR (%), mean (IQR) | 1.4 (0.96‐1.1) | 1.4 (1.0‐1.39) | <0.001 |
| Hemoglobin (g/dL), mean (IQR) | 13 (12‐15) | 12.7 (11.2‐14.5) | 0.007 |
| Platelets (/nL), mean (IQR) | 232 (185‐264) | 206 (161‐240) | <0.001 |
| HbA1c (%), mean (IQR) | 5.9 (5.4‐6.1) | 6.5 (5.6‐6.7) | <0.001 |
| FLI category, mean (IQR) | 1.2 (1.0‐2.0) | 1.6 (1.0‐2.0) | <0.001 |
| CAP (dB/m), mean (IQR) | 266 (220‐308) | 280 (224‐325) | 0.05 |
| PDGF‐β, mean (IQR) | 1,430 (1,118‐1,783) | 1,353 (963‐1,656) | 0.3 |
Abbreviations: ALT, alanine aminotransferase; EtOH, ethanol; FLI, fatty liver index; γGT, gamma‐glutamyltransferase; HbA1c, hemoglobin A1c; IQR, interquartile range; HDL, high‐density lipoprotein; INR, international normalized ratio; LDL, low‐density lipoprotein.